A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Moxr0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Patients With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy

Trial Profile

A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Moxr0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Patients With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Oct 2017

At a glance

  • Drugs MOXR 0916 (Primary) ; Atezolizumab
  • Indications Urogenital cancer
  • Focus Therapeutic Use
  • Sponsors Genentech
  • Most Recent Events

    • 06 Sep 2017 Status changed from recruiting to active, no longer recruiting.
    • 18 Jul 2017 Status changed from active, no longer recruiting to recruiting.
    • 10 Jul 2017 Planned End Date changed from 12 Jun 2022 to 25 Aug 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top